Oral Delivery of Lipophilic Drugs: The Tradeoff between Solubility Increase and Permeability Decrease When Using Cyclodextrin-Based Formulations

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Beig, Avital ^a   Agbaria, Riad ^a   Dahan, Arik ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLODEXTRIN; DEXAMETHASONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL STRAIN CACO 2; COMPLEX FORMATION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG SOLUBILITY; INTESTINE MUCOSA PERMEABILITY; INTESTINE PERFUSION; MEMBRANE PERMEABILITY; NONHUMAN; PREDICTION; RAT;

ADMINISTRATION, ORAL; ANIMALS; CACO-2 CELLS; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, LIQUID; CYCLODEXTRINS; DEXAMETHASONE; HUMANS; MALE; MOLECULAR STRUCTURE; PERMEABILITY; RATS; RATS, WISTAR; SOLUBILITY;

EID: 84880483077     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068237     Document Type: Article

References (40)

1. Dahan A, Hoffman A, (2008) Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. Journal of Controlled Release 129: 1-10.
2. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ, (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews 46: 3-26.
3. Amidon GL, Lennernas H, Shah VP, Crison JR, (1995) A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research 12: 413.
4. Dahan A, Miller JM, Amidon GL, (2009) Prediction of solubility and permeability class membership: Provisional BCS classification of the world's top oral drugs. The AAPS Journal 11: 740-746.
5. Dahan A, Miller JM, Hilfinger JM, Yamashita S, Yu LX, et al. (2010) High-permeability criterion for BCS classification: Segmental/pH dependent permeability considerations. Molecular Pharmaceutics 7: 1827-1834.
6. Lobenberg R, Amidon GL, (2000) Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. European Journal of Pharmaceutics and Biopharmaceutics 50: 3-12.
7. Dahan A, Hoffman A, (2006) Use of a dynamic in vitro lipolysis model to rationalize oral formulation development for poor water soluble drugs: Correlation with in vivo data and the relationship to intra-enterocyte processes in rats. Pharmaceutical Research 23: 2165-2174.
8. Dahan A, Hoffman A, (2007) The effect of different lipid based formulations on the oral absorption of lipophilic drugs: The ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats. European Journal of Pharmaceutics and Biopharmaceutics 67: 96-105.
9. Martinez MN, Amidon GL, (2002) A mechanistic approach to understanding the factors affecting drug absorption: A review of fundamentals. Journal of Clinical Pharmacology 42: 620-643.
10. Brewster ME, Loftsson T, (2007) Cyclodextrins as pharmaceutical solubilizers. Advanced Drug Delivery Reviews 59: 645-666.
11. Davis ME, Brewster ME, (2004) Cyclodextrin-based pharmaceutics: past, present and future. Nature Reviews Drug Discovery 3: 1023.
12. Loftsson T, Jarho P, Másson M, Järvinen T, (2005) Cyclodextrins in drug delivery. Expert Opinion on Drug Delivery 2: 335-351.
13. Stella VJ, Rao VM, Zannou EA, Zia V, (1999) Mechanisms of drug release from cyclodextrin complexes. Advanced Drug Delivery Reviews 36: 3-16.
14. Loftsson T, Brewster ME, Masson M, (2004) Role of cyclodextrins in improving oral drug delivery. American Journal of Drug Delivery 2: 261.
15. Rao VM, Stella VJ, (2003) When can cyclodextrins be considered for solubilization purposes? Journal of Pharmaceutical Sciences 92: 927-932.
16. Carrier RL, Miller LA, Ahmed I, (2007) The utility of cyclodextrins for enhancing oral bioavailability. Journal of Controlled Release 123: 78.
17. Dahan A, Miller JM, Hoffman A, Amidon GE, Amidon GL, (2010) The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: Mechanistic modeling and application to progesterone. Journal of Pharmaceutical Sciences 99: 2739-2749.
18. Gamsiz E, Miller L, Thombre A, Ahmed I, Carrier RL, (2010) Modeling the influence of cyclodextrins on oral absorption of low-solubility drugs: I. model development. Biothechnology and Bioengineering 105: 409-420.
19. Gamsiz E, Thombre A, Ahmed I, Carrier RL, (2011) Drug salts and solubilization: modeling the influence of cyclodextrins on oral absorption. Annals of Biomedical Engineering 39: 455-468.
20. Gamsiz ED, Miller L, Thombre AG, Ahmed I, Carrier RL, (2010) Modeling the influence of cyclodextrins on oral absorption of low solubility drugs: II. Experimental validation. Biotechnology and Bioengineering 105: 421-430.
21. Loftsson T, Vogensen SB, Brewster ME, Konrá{eth}sdóttir F, (2007) Effects of cyclodextrins on drug delivery through biological membranes. Journal of Pharmaceutical Sciences 96: 2532-2546.
22. Miller JM, Dahan A, (2012) Predicting the solubility-permeability interplay when using cyclodextrins in solubility-enabling formulations: Model validation. International Journal of Pharmaceutics 430: 388-391.
23. Yalkowsky SH, (2012) Perspective on improving passive human intestinal absorption. Journal of Pharmaceutical Sciences 101: 3047-3050.
24. Beig A, Miller JM, Dahan A, (2012) Accounting for the solubility-permeability interplay in oral formulation development for poor water solubility drugs: The effect of PEG-400 on carbamazepine absorption. European Journal of Pharmaceutics and Biopharmaceutics 81: 386-391.
25. Dahan A, Miller J, (2012) The solubility-permeability interplay and its implications in formulation design and development for poorly soluble drugs. The AAPS Journal 14: 244-251.
26. Miller JM, Beig A, Carr RA, Webster GK, Dahan A, (2012) The solubility-permeability interplay when using cosolvents for solubilization: Revising the way we use solubility-enabling formulations. Molecular Pharmaceutics 9: 581-590.
27. Miller JM, Beig A, Krieg BJ, Carr RA, Borchardt TB, et al. (2011) The solubility-permeability Interplay: Mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation. Molecular Pharmaceutics 8: 1848-1856.
28. Higuchi T, Connors KA, (1965) Phase-solubility techniqes. Advances in Analytical Chemistry and Instrumentation 4: 117-212.
29. Higuchi T, Kristiansen H, (1970) Binding specificity between small organic solutes in aqueous solution: classification of some solutes into two groups according to binding tendencies. Journal of Pharmaceutical Sciences 59: 1601-1608.
30. Wohnsland F, Faller B, (2001) High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. Journal of Medicinal Chemistry 44: 923-930.
31. Dahan A, Lennernäs H, Amidon GL, (2012) The fraction dose absorbed, in humans, and high jejunal human permeability relationship. Molecular Pharmaceutics 9: 1847-1851.
32. Fairstein M, Swissa R, Dahan A, (2013) Regional-dependent intestinal permeability and BCS classification: Elucidation of pH-related complexity in rats using pseudoephedrine. The AAPS Journal 15: 589-597.
33. Dahan A, Amidon GL, (2009) Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: The role of efflux transport in the oral absorption of BCS class III drugs. Molecular Pharmaceutics 6: 19-28.
34. Dahan A, Amidon GL, (2009) Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. American Journal of Physiology- Gastrointestinal and Liver Physiology 297: G371-G377.
35. Dahan A, Sabit H, Amidon G, (2009) The H2 receptor antagonist nizatidine is a P-gp substrate: Characterization of its intestinal epithelial cell efflux transport. The AAPS Journal 11: 205-213.
36. Dahan A, Amidon G, (2009) Grapefruit juice and its constituents augment colchicine intestinal absorption: Potential hazardous interaction and the role of P-gp. Pharmaceutical Research 26: 883-892.
37. Dahan A, Amidon GL, (2010) MRP2 mediated drug-drug interaction: Indomethacin increases sulfasalazine absorption in the small intestine, potentially decreasing its colonic targeting. International Journal of Pharmaceutics 386: 216-220.
38. Dahan A, Sabit H, Amidon GL, (2009) Multiple efflux pumps are involved in the transepithelial transport of colchicine: Combined effect of P-gp and MRP2 leads to decreased intestinal absorption throughout the entire small intestine. Drug Metabolism and Disposition 37: 2028-2036.
39. Dahan A, Beig A, Ioffe-Dahan V, Agbaria R, Miller J, (2013) The twofold advantage of the amorphous form as an oral drug delivery practice for lipophilic compounds: Increased apparent solubility and drug flux through the intestinal membrane. The AAPS Journal 15: 347-353.
40. Miller JM, Beig A, Carr RA, Spence JK, Dahan A, (2012) A win-win solution in oral delivery of lipophilic drugs: Supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability. Molecular Pharmaceutics 9: 2009-2016.